Stockscreener 앱 받기
32.38
0.89%
-0.04
전일 마감가:
$32.42
열려 있는:
$32.57
하루 거래량:
3,176
Relative Volume:
0.01
시가총액:
$1.62B
수익:
$345.60M
순이익/손실:
$-79.01M
주가수익비율:
-25.25
EPS:
-1.2822
순현금흐름:
$-18.62M
1주 성능:
-1.50%
1개월 성능:
-3.54%
6개월 성능:
-37.00%
1년 성능:
-28.84%
1일 변동 폭
$31.75
$32.70
1주일 범위
$30.52
$33.61
52주 변동 폭
$29.72
$76.98
이뮤노코어 홀딩스 Stock (IMCR) Company Profile
명칭
Immunocore Holdings Plc Adr
전화
01235 5430281
주소
90 PARK DRIVE, OXFORDSHIRE
IMCR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| IMCR | 32.20 | 1.62B | 345.60M | -79.01M | -18.62M | -1.2822 |
| VRTX | 447.95 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.90 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.67 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.92 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.56 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
이뮤노코어 홀딩스 Stock (IMCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-11-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-31 | 개시 | Robert W. Baird | Outperform |
| 2023-09-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-09-13 | 개시 | Needham | Buy |
| 2023-08-16 | 개시 | CapitalOne | Overweight |
| 2023-07-17 | 개시 | Canaccord Genuity | Hold |
| 2023-03-31 | 개시 | Mizuho | Buy |
| 2023-03-30 | 개시 | Guggenheim | Buy |
| 2023-03-24 | 개시 | Bryan Garnier | Buy |
| 2022-12-16 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-11-30 | 개시 | Barclays | Overweight |
| 2022-09-09 | 개시 | Morgan Stanley | Overweight |
| 2022-09-08 | 개시 | Ladenburg Thalmann | Buy |
| 2022-08-08 | 개시 | Cowen | Outperform |
| 2022-08-02 | 개시 | BTIG Research | Buy |
| 2022-02-08 | 개시 | H.C. Wainwright | Buy |
| 2021-10-20 | 개시 | Oppenheimer | Outperform |
| 2021-03-02 | 개시 | Goldman | Neutral |
| 2021-03-02 | 개시 | JP Morgan | Overweight |
| 2021-03-02 | 개시 | Jefferies | Buy |
모두보기
이뮤노코어 홀딩스 주식(IMCR)의 최신 뉴스
FATE Presents Encourgaing Data From Lupus Study, Stock Gains - Barchart
Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study - Nasdaq
Immunocore (IMCR) Upgraded to Buy: Here's Why - MSN
Immunocore's SWOT analysis: biotech stock faces pivotal moment amid PRAME data - Investing.com India
FATE Q3 Earnings Beat On Higher Revenues, Pipeline In Focus - Barchart
SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark - Barchart
Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised - Barchart
Mizuho downgrades Immunocore stock to Neutral, slashes PT to $38 from $72 - Investing.com
Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline In Focus - Barchart
3 Fast-Growing Stocks Analysts See Doubling In Price - Barchart
Immunocore repays Pharmakon loan, ends agreement - Investing.com India
PBYI Beats Q3 Earnings & Revenue Estimates, Revises '24 View, Stock Up - Barchart
Wall Street Analysts Predict an 112.56% Upside in Immunocore (IMCR): Here's What You Should Know - Yahoo Finance
Immunocore Holdings earnings beat by $0.50, revenue topped estimates - Investing.com India
Immunocore stock hits 52-week low at $29.72 amid market challenges - Investing.com
Immunocore's SWOT analysis: biotech stock poised for growth amid clinical trials - Investing.com UK
Financial Fitness Check: Examining Immunocore Holdings plc ADR (IMCR)’s Key Ratios - The Dwinnex
Immunocore stock hits 52-week low at $32.07 amid market challenges - Investing.com
TD Cowen maintains Buy rating on Immunocore shares on ovarian cancer drug data - Investing.com India
Quarterly Metrics: Quick and Current Ratios for Immunocore Holdings plc ADR (IMCR) - The Dwinnex
Immunocore Holdings plc ADR (IMCR) is looking forward to a strong quarter - SETE News
Immunocore stock hits 52-week low at $32.84 amid market challenges - Investing.com
Ratios Revealed: Decoding Immunocore Holdings plc ADR (IMCR)’s Financial Health - The Dwinnex
Have you been able to find a good deal on Immunocore Holdings plc ADR’s shares? - US Post News
Immunocore Holdings plc (IMCR): Top ADR Stock According to Hedge Funds - Yahoo Finance UK
The growth track for Immunocore Holdings plc ADR (IMCR) has changed recently - SETE News
The Potential Rise in the Price of Sun Communities, Inc. (SUI) following insiders activity - Knox Daily
Insider Sale Alert: Terns Pharmaceuticals Inc [TERN] – Is it Time to sell? - Knox Daily
Immunocore Holdings plc ADR (IMCR) may enjoy gains as insiders got busy in the recent days - Knox Daily
Monitoring Brookline Bancorp, Inc. (BRKL) after recent insider movements - Knox Daily
Immunocore Holdings plc ADR [IMCR] Shares Fall -4.18% on Thursday - Knox Daily
Financial Health Report: Immunocore Holdings plc ADR (IMCR)’s Ratios Tell a Tale - The Dwinnex
Insider Sale: President Brian Hole Sells Shares of Willis Lease Finance Corp (WLFC) - Yahoo Finance UK
IMCR’s 52-Week Rollercoaster: From $33.04 to $76.98 – What’s Next for Investors? - The InvestChronicle
Immunocore CFO to depart, company seeks replacement - Investing.com
IMCR’s price-to-free cash flow ratio: How it affects investment decisions - US Post News
Immunocore Holdings plc ADR [IMCR] Insider Activity: An Update for Investors - Knox Daily
Top 10 ADR Stocks To Buy According to Hedge Funds - Insider Monkey
Ratio Examination: Immunocore Holdings plc ADR (IMCR)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Examining the Potential Price Growth of Immunocore Holdings plc ADR (IMCR) - Knox Daily
Cancer Immunotherapy Market Size Expected to Touch USD 530.2 Billion by 2034, With 14.2% CAGR Growth: Prophecy Market Insights - GlobeNewswire Inc.
South Korea Cancer Immunotherapy Market Size & Outlook, 2030 - Grand View Research
Brazil Cancer Immunotherapy Market Size & Outlook, 2030 - Grand View Research
Potential Price Increase for Immunocore Holdings plc ADR (IMCR) After Recent Insider Activity - Knox Daily
Mizuho backs Outperform rating for Immunocore stock despite PT cut - Investing.com
Earnings call: Immunocore reports robust growth for KIMMTRAK in Q2 - Investing.com India
It would be worthwhile to take a closer look at Immunocore Holdings plc ADR (IMCR) - US Post News
Insider Selling Buzz: Immunocore Holdings plc ADR [IMCR] CHIEF HR OFFICER St Leger Tina Amber sold 4,375 shares of the company – Knox Daily - Knox Daily
An Analysis of Immunocore Holdings plc ADR (IMCR)’s Potential Price Growth - Knox Daily
Trading Day Review: Immunocore Holdings plc ADR (IMCR) Loses Momentum, Closing at 38.87 - The Dwinnex
Prepare Yourself for Liftoff: Immunocore Holdings plc ADR (IMCR) - SETE News
이뮤노코어 홀딩스 (IMCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
이뮤노코어 홀딩스 주식 (IMCR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| St Leger Tina Amber | CHIEF HR OFFICER |
Apr 01 '24 |
Sale |
64.06 |
4,375 |
280,262 |
0 |
| Berman David M | HEAD OF R&D |
Feb 28 '24 |
Option Exercise |
17.46 |
36,509 |
637,447 |
36,509 |
| Berman David M | HEAD OF R&D |
Feb 28 '24 |
Sale |
68.59 |
36,509 |
2,504,158 |
0 |
| Berman David M | HEAD OF R&D |
Feb 27 '24 |
Option Exercise |
17.46 |
54,938 |
959,217 |
54,938 |
| Berman David M | HEAD OF R&D |
Feb 26 '24 |
Option Exercise |
17.46 |
28,553 |
498,535 |
28,553 |
| Berman David M | HEAD OF R&D |
Feb 27 '24 |
Sale |
70.86 |
54,938 |
3,893,030 |
0 |
| Berman David M | HEAD OF R&D |
Feb 26 '24 |
Sale |
70.65 |
28,553 |
2,017,288 |
0 |
| St Leger Tina Amber | Chief HR Officer |
Jan 03 '24 |
Option Exercise |
29.87 |
4,375 |
130,681 |
4,375 |
| St Leger Tina Amber | Chief HR Officer |
Jan 03 '24 |
Sale |
69.89 |
4,375 |
305,781 |
0 |
0.42%
0.16%
자본화:
|
볼륨(24시간):